RANCHO SANTA MARGARITA, Calif., April 28, 2003 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) announces that the prestigious trade journal IVD Technology (In-vitro Diagnostic Technology) has invited BioCurex's President, Dr. Ricardo Moro, to write an article to be published in the journal.
The invitation to write the article in the journal was the result of a presentation by Dr. Moro on the RECAF(TM) technology in a cancer congress where many of the major drug companies attended.
The article will focus on the applications of the Histo-RECAF(TM) kit that has recently obtained FDA approval and is included in the patent granted by the US Patent Office and granted or pending in over 20 other countries.
The worldwide market potential for the Histo-RECAF(TM) line of kits is estimated to be over $200 million a year within 5 years.
IVDT, a publication of the Canon Communications group, is the only controlled circulation trade journal devoted exclusively to the development and manufacturing of in-vitro diagnostics. Practical, high quality editorial meets the needs of all technical and management personnel in the in-vitro diagnostics industry. The publication is done in full color. IVDT circulation is over 15,000/issue (9 issues a year). The magazine delivers extensive coverage to technical and management personnel from the in-vitro diagnostics industry, including subscribers from leading diagnostic companies such as:
-- Abbott Laboratories -- Bayer Corp., Diagnostics Division -- Beckman Coulter Inc. -- Becton Dickinson -- Bio-Rad Laboratories Inc. -- bioMerieux -- Biosite Diagnostics -- Dade Behring Inc. -- Diagnostic Products Corp. -- Gen-Probe Inc. -- Instrumentation Laboratory -- Organon Teknika -- Quidel -- Roche Diagnostics
According to the publisher, 80% of its readers take action after seeing an advertisement in IVD Technology and 86% of its readers are involved in the purchasing process of products and services for their companies. For more information visit IVDT website at http://www.canonmediakit.com/ivd.
Dr. Moro, President of BioCurex, stated: "In science, we produce results, we write an article and we submit it for publication. The competition for printed space is so fierce that the term "Publish-or-Perish" has become part of the language. Fifty to ninety percent of papers are rejected, depending on the journal. In contrast to that common practice, we have been invited to submit an article. I am ecstatic for the honor this invitation represents. It validates the Histo-RECAF(TM) in the eyes of the editors of a magazine that is solely dedicated to clinical diagnostic products. Also, it will present our technology not only to users, but also to a large audience within major corporations some of which have already expressed an interest in licensing it."
About Histo-RECAF(TM) and Cryo-RECAF(TM)
These kits stain cancer cells but not most normal cells in biopsies and tissue samples. This facilitates the work of the pathologist who has to look at the preparation under a microscope and inform the surgeon whether the patient has cancer or not. Computerized systems that use a video camera and intelligent software to examine samples can also greatly benefit from the Histo-RECAF(TM) staining since the computer can now focus on the stained cells rather than analyzing everything that looks like a cell. This saves a substantial amount of time thus increasing the put through of each apparatus.
About BioCurex
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. Detailed information about BioCurex may be obtained from their website at http://www.biocurex.com.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.